These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33614907)

  • 21. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
    Fenwick C; Turelli P; Pellaton C; Farina A; Campos J; Raclot C; Pojer F; Cagno V; Nusslé SG; D'Acremont V; Fehr J; Puhan M; Pantaleo G; Trono D
    Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34257144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection.
    Wieczorek L; Zemil M; Merbah M; Dussupt V; Kavusak E; Molnar S; Heller J; Beckman B; Wollen-Roberts S; Peachman KK; Darden JM; Krebs S; Rolland M; Peel SA; Polonis VR
    Front Immunol; 2022; 13():901217. PubMed ID: 35711449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
    Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
    SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    Muralidar S; Gopal G; Visaga Ambi S
    J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A high-throughput screening system for SARS-CoV-2 entry inhibition, syncytia formation and cell toxicity.
    Jancy SV; Lupitha SS; Chandrasekharan A; Varadarajan SN; Nelson-Sathi S; Prasad R; Jones S; Easwaran S; Darvin P; Sivasailam A; Santhoshkumar TR
    Biol Proced Online; 2023 Jul; 25(1):22. PubMed ID: 37495994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
    Walls AC; Park YJ; Tortorici MA; Wall A; McGuire AT; Veesler D
    Cell; 2020 Apr; 181(2):281-292.e6. PubMed ID: 32155444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants.
    Li B; Zhao Y; Wu X; Wu H; Tang W; Yu X; Mou J; Tan W; Jin M; Li W; Zhang Q; Liu M
    ACS Nano; 2023 Apr; 17(7):7017-7034. PubMed ID: 36971310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
    Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis.
    Gorshkov K; Susumu K; Chen J; Xu M; Pradhan M; Zhu W; Hu X; Breger JC; Wolak M; Oh E
    ACS Nano; 2020 Sep; 14(9):12234-12247. PubMed ID: 32845122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
    Wang WJ; Chen Y; Su WC; Liu YY; Shen WJ; Chang WC; Huang ST; Lin CW; Wang YC; Yang CS; Hou MH; Chou YC; Wu YC; Wang SC; Hung MC
    J Food Biochem; 2022 Oct; 46(10):e14354. PubMed ID: 35894128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luciferase-based quantification of membrane fusion induced by SARS-CoV-2 S protein.
    Haga K; Takai-Todaka R; Sawada A; Katayama K
    Genes Cells; 2022 Aug; 27(8):537-543. PubMed ID: 35488742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
    Verma D; Church TM; Swaminathan S
    J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.